TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30415782

Group type: EXPERIMENTAL
Intervention: Exceptional human experiences (EHEs) reported by scientists and engineers
Number of subjects: 999

Group type: COMPARATOR
Intervention: Exceptional human experiences (EHEs) reported by the general population
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Exceptional human experiences (EHEs) reported by enthusiasts
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Paranormal belief levels
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Correlation between belief and experience
Number of subjects: 999
Study: 26704258

Group type: EXPERIMENTAL
Intervention: Epidural Cortical Stimulation (CS) combined with intensive language therapy (3 hours a day for 6 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Epidural Cortical Stimulation (CS) combined with intensive language therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Epidural Cortical Stimulation (CS)
Number of subjects: 8
Study: 25306677

Group type: EXPERIMENTAL
Intervention: RIPC applied during sevoflurane anesthesia (RIPCsevo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 48

Group type: COMPARATOR
Intervention: RIPC applied during propofol anesthesia (RIPCprop)
Number of subjects: 48
Study: 22309641

Group type: EXPERIMENTAL
Intervention: Psycho-educational secondary prevention program 'En nu ik...!'
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control program offering positive attention, recreation, distraction, warmth, and empathy
Number of subjects: 140
Study: 20103451

Group type: EXPERIMENTAL
Intervention: Discount coupon for oral contraceptive pills (OCPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no coupon)
Number of subjects: 0
Study: 17907147

Group type: EXPERIMENTAL
Intervention: Rehabilitation program integrating exercise, self-management, and active coping strategies (ESCAPE-knee pain)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Individual rehabilitation
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Group rehabilitation
Number of subjects: 418

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 418
Study: 16256766

Group type: EXPERIMENTAL
Intervention: Contract for Change + Food Guide Pyramid lessons
Number of subjects: 38

Group type: COMPARATOR
Intervention: Food Guide Pyramid lessons
Number of subjects: 38
Study: 11152898

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (800 mg) and topical benzocaine (20%)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Oral placebo and topical benzocaine (20%)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg) and topical placebo
Number of subjects: 99

Group type: COMPARATOR
Intervention: Oral placebo and topical placebo
Number of subjects: 99
Study: 9547774

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local peribulbar block
Number of subjects: 30
Study: 7981922

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigated drugs
Number of subjects: 0
Study: 3597241

Group type: EXPERIMENTAL
Intervention: 0.30 ppm O3
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.60 ppm NO2
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.60 ppm NO2 plus 0.30 ppm O3
Number of subjects: 40
Study: 31494028

Group type: EXPERIMENTAL
Intervention: Morphine Parent/Nurse Controlled Analgesia (PNCA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Continuous Opioid Infusion (COI)
Number of subjects: 25
Study: 29909156

Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 9300

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 9300
Study: 27563320

Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Squatting position
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All three positions
Number of subjects: 96
Study: 24748338

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg tablets, twice per week for 12 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: LHRH agonist (decapeptyl, 3.75 mg subcutaneous, single injection, once a month for 3 months)
Number of subjects: 140
Study: 23735004

Group type: EXPERIMENTAL
Intervention: diet and orlistat
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: diet, orlistat and exercise
Number of subjects: 67

Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 67
Study: 21256927

Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19712544

Group type: EXPERIMENTAL
Intervention: Text messaging reminder
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 931

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 931
Study: 17133193

Group type: EXPERIMENTAL
Intervention: Nursing intervention in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 15334276

Group type: EXPERIMENTAL
Intervention: Ciclopirox (Loprox) gel
Number of subjects: 0
Study: 11041471

Group type: EXPERIMENTAL
Intervention: Arrow-Trerotola percutaneous thrombolytic device (PTD)
Number of subjects: 10
Study: 9024265

Group type: EXPERIMENTAL
Intervention: Cyclical hPTH-(1-34) (800 U)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyclical hPTH-(1-34) + sequential calcitonin (75 U/day)
Number of subjects: 30
Study: 8111174

Group type: EXPERIMENTAL
Intervention: Exchange transfusion (study group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No exchange transfusion (control group)
Number of subjects: 30
Study: 6696209

Group type: EXPERIMENTAL
Intervention: Repeated conjunctival provocation tests (CPT)
Number of subjects: 20
Study: 30712954

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both ADA and AZA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients without endoscopic recurrence
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CDAI score correlation
Number of subjects: 61
Study: 29940266

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, n=14)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-exercising Control (CON, n=12)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined High-Intensity Interval and Resistance Training (HIIT+RT, n=13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT, n=12)
Number of subjects: 51
Study: 27394381

Group type: EXPERIMENTAL
Intervention: Routine low dose aspirin (LDA) 75 mg once daily from first trimester until 36-week gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LDA based on a positive first trimester screening test
Number of subjects: 0
Study: 24495314

Group type: EXPERIMENTAL
Intervention: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in high-fat fed state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in fasted state
Number of subjects: 24
Study: 20456259

Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No anterior chamber paracentesis (Group B)
Number of subjects: 41
Study: 20972900

Group type: EXPERIMENTAL
Intervention: MSCT combined with CRP
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MSCT combined with FIB
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MSCT combined with SAA
Number of subjects: 3

Group type: COMPARATOR
Intervention: MSCT combined with CRP, FIB, and SAA
Number of subjects: 3
Study: 17950795

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 1380
Study: 17242663

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC) without EPO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC) with EPO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide vs BSC
Number of subjects: 0
Study: 15360893

Group type: EXPERIMENTAL
Intervention: KNAVE-II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper or ESS
Number of subjects: 0
Study: 10804778

Group type: EXPERIMENTAL
Intervention: High-sodium diet (300 mmol sodium/d, HS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low-sodium diet (30 mmol sodium/d, LS)
Number of subjects: 47
Study: 8634878

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 50 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg + pseudoephedrine 60 mg (A + P)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 1628531

Group type: EXPERIMENTAL
Intervention: Social support group meetings (8 meetings)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (intensive outpatient diabetes training program only)
Number of subjects: 204
Study: 6378232

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (100 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30898204

Group type: EXPERIMENTAL
Intervention: Testosterone (1%) gel for 12 weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 151
Study: 29247029

Group type: EXPERIMENTAL
Intervention: Shorter-time application protocol (1 application lasting electric block time to effect plus 60- and 120-second freeze bonus)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional strategy (180-second cryoballoon applications per vein with a bonus freeze)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Shorter-time application protocol
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 27128212

Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.1, 0.3, 1, 3, 10, 30, 60, and 100 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 22983456

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/kg)
Number of subjects: 50
Study: 22097138

Group type: EXPERIMENTAL
Intervention: Xiaozhong Zhitong mixture (50 ml every time, twice a day for 4 weeks)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg every time, twice a day)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sham group (no preventing treatment)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Harris scoring, PAHSS, and IAHSS
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Gastrointestinal reactions
Number of subjects: 154
Study: 19186712

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with tropisetron (5 mg daily for 6 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham acupuncture combined with tropisetron (5 mg daily for 6 days)
Number of subjects: 66
Study: 16583282

Group type: EXPERIMENTAL
Intervention: Simulator-based teaching (MI simulation followed by RAD lecture)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional instruction (RAD simulation followed by MI lecture)
Number of subjects: 38
Study: 14521826

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 10897186

Group type: EXPERIMENTAL
Intervention: Dissemination package with implementation manuals, staff training workshops, and follow-up consultation calls
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dissemination package with implementation manuals and staff training workshops
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dissemination package with implementation manuals only
Number of subjects: 74
Study: 8832449

Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 1 mg, LI = 6 min (Group 1‐6)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 1.5 mg, LI = 9 min (Group 1.5‐9)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 2 mg, LI = 12 min (Group 2‐12)
Number of subjects: 75
Study: 1418836

Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 6536490

Group type: EXPERIMENTAL
Intervention: Specific training for compliance with walking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving only attention
Number of subjects: 60
Study: 30725077

Group type: EXPERIMENTAL
Intervention: Youth‐Nominated Support Team Intervention (YST) plus Treatment as Usual (TAU)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 448
Study: 30004900

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (ILE) 5.25 mL/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26976418

Group type: EXPERIMENTAL
Intervention: RT plus AS (androgen suppression)
Number of subjects: 819

Group type: COMPARATOR
Intervention: RT
Number of subjects: 819
Study: 24505216

Group type: EXPERIMENTAL
Intervention: Educational toolkit (received in June 2009)
Number of subjects: 933789

Group type: COMPARATOR
Intervention: Control group (received no educational toolkit until May 2010)
Number of subjects: 933789
Study: 23110040

Group type: EXPERIMENTAL
Intervention: Feedback intervention (20 mins/week for 4 weeks of observation, feedback, and personalized action planning)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feedback intervention (for implementing wards)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fidelity to intervention
Number of subjects: 60
Study: 20619748

Group type: EXPERIMENTAL
Intervention: No clinically relevant change in pain intensity in the first 3 months
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: No clinically relevant change in disability status in the first 3 months
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Higher pain intensity score at baseline
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Higher score for kinesiophobia
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Clinically relevant decrease in pain intensity in the first 3 months
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Clinically relevant decrease in disability status in the first 3 months
Number of subjects: 628
Study: 17342480

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg once daily for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nevirapine 200 mg combined with itraconazole 200 mg once daily for 7 days
Number of subjects: 12
Study: 16359503

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg day(-1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11824492

Group type: EXPERIMENTAL
Intervention: Single-family behavioral family therapy (BFT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Relatives group (RG)
Number of subjects: 87
Study: 9551874

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg-360 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8000153

Group type: EXPERIMENTAL
Intervention: Peripheral IVN (75% nonprotein calories supplied as lipid, n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Central IVN (n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both Peripheral IVN and Central IVN
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peripheral IVN
Number of subjects: 18

Group type: COMPARATOR
Intervention: Central IVN
Number of subjects: 18
Study: 2899590

Group type: EXPERIMENTAL
Intervention: 1.5g cephradine intramuscularly preoperatively and 1g cephradine orally before removal of the urethral catheter
Number of subjects: 142

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 142
Study: 31858883

Group type: EXPERIMENTAL
Intervention: Lionheart Camp for Kids
Number of subjects: 12
Study: 29311763

Group type: EXPERIMENTAL
Intervention: Multi-ingredient pre-workout supplement (MIPS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28142344

Group type: EXPERIMENTAL
Intervention: NTS group (three-site injection technique)
Number of subjects: 85

Group type: COMPARATOR
Intervention: SSI group (single-site injection technique)
Number of subjects: 85
Study: 26429605

Group type: EXPERIMENTAL
Intervention: Vancomycin (mean 12.8 mg/kg every 12 hours for 7 patients, every 8 hours for 1 patient, every 24 hours for 1 patient)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 9
Study: 24565128

Group type: EXPERIMENTAL
Intervention: Head rotation 45° laterally in prone position (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Strictly neutral prone position (Group I)
Number of subjects: 45
Study: 21603891

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg) + Ethanol (0.3 g/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ethanol (0.3 g/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxycodone (10 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg) + Ethanol (0.6 g/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Active drug conditions (Oxycodone and Ethanol)
Number of subjects: 14
Study: 18458039

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg once daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lapatinib 500 mg twice daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lapatinib (both dosing schedules)
Number of subjects: 138
Study: 17263263

Group type: EXPERIMENTAL
Intervention: Manual vital capacity manoeuvre (VCM) before weaning off CPB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) of 10 cmH2O during CPB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) of 7 cmH2O after weaning off CPB
Number of subjects: 30
Study: 12973963

Group type: EXPERIMENTAL
Intervention: Propofol alone (1.5 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane alone (5% in oxygen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined propofol-sevoflurane (1.5 mg/kg propofol followed by 5% sevoflurane in oxygen)
Number of subjects: 50
Study: 11058207

Group type: EXPERIMENTAL
Intervention: Education program based on self‐management (group E)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care (control group C)
Number of subjects: 188
Study: 9223888

Group type: EXPERIMENTAL
Intervention: Inhalation of 3 l.min‐1 oxygen via a mask for initial 3 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 24
Study: 8429447

Group type: EXPERIMENTAL
Intervention: Beclomethasone (50 micrograms nebulized, 3 doses per day for 28 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline solution (placebo, 3 doses per day for 28 days)
Number of subjects: 13
Study: 3597249

Group type: EXPERIMENTAL
Intervention: Various O2‐N2 mixtures (FIO2 = 20.93, 17.39, 14.40, 11.81%) during treadmill run
Number of subjects: 9
Study: 30415610

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (15 to 20 mg weekly)
Number of subjects: 4786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4786
Study: 27922745

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg q.12h
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg q.8h
Number of subjects: 572
Study: 25900168

Group type: EXPERIMENTAL
Intervention: Genital inflammation (elevated levels of at least 5 of 9 inflammatory cytokines)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Matched uninfected controls (no genital inflammation)
Number of subjects: 58
Study: 24949292

Group type: EXPERIMENTAL
Intervention: Heparin (1000 IU)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 96
Study: 21450597

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Continuous Moderate-Intensity Exercise (CME)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study: 19410103

Group type: EXPERIMENTAL
Intervention: Centralized telecare management coupled with automated home-based symptom monitoring
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 405
Study: 17526535

Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 18

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FTY720 to MMF conversion
Number of subjects: 18
Study: 14738234

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (18 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11960657

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9655012

Group type: EXPERIMENTAL
Intervention: Animated targets viewed in isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animated targets viewed sliding along one side of a larger stationary object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animated targets viewed sliding between two larger stationary objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animated targets of varying sizes
Number of subjects: 0
Study: 7650229

Group type: EXPERIMENTAL
Intervention: Transderm‐Nitro
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nitrodisc
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nitro‐Dur II
Number of subjects: 18
Study: 2667333

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 1262715

Group type: EXPERIMENTAL
Intervention: Streptomycin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 42